BioSpace News Archive

Exscientia announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March:

The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.

AbbVie today announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.

Element Biosciences, Inc. today announced a partnership with Watchmaker Genomics demonstrating the value and performance of Watchmaker’s DNA and RNA Library Prep Kits on Element’s AVITI System.

Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce histology data from their intranasal ALPHA-1062 Traumatic Brain Injury (TBI) program.

Celebrity Moderators Amy Poehler, Dan Fogelman, Ben Feldman, Steve Aoki, Susan Schneider Williams, Adam Shapiro, Pamela Adlon, Caitlin Reilly, Richard Lui, and T.J. Oshie Join Seth Rogen and Lauren Miller Rogen For CareCon On National Caregivers Day.

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), and Vifor Pharma Group (Vifor Pharma), today announced that the companies have amended and restated the terms of their license agreement, pursuant to which Akebia Therapeutics, Inc. (Akebia) granted Vifor Pharma an exclusive license to sell vadadustat, Akebia’s investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (CKD).